B7-33 vs CoQ10
A side-by-side research comparison of B7-33 and CoQ10 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | B7-33 | CoQ10 |
|---|---|---|
| Full name | B7-33 (Relaxin Peptide Analog) | Coenzyme Q10 (Ubiquinol) |
| Category | Cardiovascular | Cardiovascular |
| Status | Research peptide (preclinical) | Dietary supplement |
| Mechanism | Selectively activates the relaxin receptor RXFP1 pathway, biasing signaling toward anti-fibrotic effects. It reduces collagen deposition and promotes healthy tissue remodeling in heart, lung, and kidney models without some downsides of full-length relaxin. | Shuttles electrons in the mitochondrial respiratory chain (Complex I→III). As ubiquinol, neutralizes lipid peroxyl radicals protecting cell membranes and LDL from oxidation. Restores mitochondrial membrane potential. |
| Molecular weight | ~3.3 kDa | 863.34 Da |
| Half-life | Short (peptide) | ~33 hours (ubiquinol) |
| Bioavailability | Injection (research) | ~6-9% (standard); ~300% improved with ubiquinol/lipid formulations |
| Typical dose | Not established for humans | 100-300 mg ubiquinol |
| Frequency | Research only | Daily with fat-containing meal |
| Route | Injection (research) | Oral softgel |
B7-33 reported benefits
- Anti-fibrotic effects (preclinical)
- Cardiac and organ protection (research)
- Healthy tissue remodeling
- Relaxin-pathway (RXFP1) biased signaling
CoQ10 reported benefits
- Mitochondrial energy production
- Cardiac function support
- Antioxidant protection
- Statin side effect mitigation
- Exercise performance
- Fertility support (egg/sperm quality)
Related comparisons
Research and educational reference only. Not medical advice.